Table 3 Probability of survival according to radiological response at 6, 12, 24 and 48 months

From: Peptide receptor radionuclide therapy with 90Y-DOTATATE/90Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity

Radiological response

Time (months)

Deaths

Survivor function

Progressive disease

6

1

0.9286

 

12

3

0.7143

 

24

5

0.3571

 

48

1

0.2381

Stable disease

6

1

0.9565

 

12

0

0.9565

 

24

3

0.8261

 

48

4

0.5872

Positive response

6

0

1

 

12

0

1

 

24

1

0.9167

 

48

3

0.5432